Silexion Therapeutics 执行 1 比 9 的反向股票拆分,以满足纳斯达克的价格要求。
Silexion Therapeutics executes 1-for-9 reverse stock split to meet Nasdaq price requirements.
生物技术公司Silexion Therapeutics正在开发针对某些癌症的RNA干扰疗法,该公司将在2024年11月27日市场关闭后实施1比9的反向股份分割.
Silexion Therapeutics, a biotech firm developing RNA interference therapies for certain cancers, is implementing a 1-for-9 reverse share split effective after market close on November 27, 2024.
此举旨在帮助该公司满足Nasdaq的最低投标价格要求,支持其市场地位,并促进未来股票融资。
This move aims to help the company meet Nasdaq’s minimum bid price requirement, support its market position, and facilitate future equity financings.
分割将调整交易价格和股票的平价价值,而无需通过经纪人持有股票的股东采取任何行动。
The split will adjust the trading price and par value of shares, with no action needed from shareholders holding shares through brokers.